BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is spotlighted in a recent episode of the “Test. Optimize. Scale.” podcast series, which features industry leaders and pioneers sharing insights and experiences of growing their businesses to scale. BiondVax CEO Amir Reichman is a guest of the popular on-demand podcast, which is hosted by Jason Fishman, SVP Digital Strategy for Digital Niche Agency. During the podcast, Reichman talked about his journey leading up to joining BiondVax in 2021 as well as the company’s current plans, which include developing a derisked pipeline of diversified and commercially viable products and platforms, including an innovative nanosized antibody (“NanoAb”) pipeline licensed from the Max Planck Society. “[BiondVax] had a company with a super team that knew how to develop drugs from zero to 100 and manage budget,” said BiondVax CEO Amir Reichman during the podcast. “They had massive labs and facilities. . . . However, they had $2.5 million in the bank and the IP [for its universal influenza vaccine] had basically flopped [in a phase 3 trial]. . . .It was an excellent opportunity. . . to in-license a new technology to the company. It becomes a new company in a very early stage, but with a massive edge over others. The team is super experienced in running trials. . . the capacity and capabilities are there. If we raise enough money with a nice business plan, we can in-license a technology and have a good start.”
To listen to the full interview, visit https://ibn.fm/YHtWc
To view the full press release, visit https://ibn.fm/fXAD9
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its prior vaccine candidate; the company has also built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
